Kervalion

50% of dental implant procedures require a bone graft due to jawbone loss or deficiency. Current solutions are suboptimal and burdensome for both patients and practitioners.

Autografts, which involve taking bone from the patient, require a second surgical site, increasing pain, risk, and recovery time. Alternatives such as animal-derived, human-derived, or synthetic grafts involve complex preparation, membranes, and multi-step procedures, making the surgery longer and technically challenging. These limitations mean that only specialist surgeons can reliably perform bone grafting, while general practitioners often cannot.

For patients, these procedures often require 2 to 3 surgeries over a period of 6 to 9 months, leading to prolonged discomfort, higher risk of infection, and delayed implant placement. Failure rates can reach up to 20%, resulting in additional surgeries, higher costs, and decreased quality of life. For the healthcare system, this translates into increased treatment costs, longer hospital or clinic occupancy, and reduced access for patients. In short, the current standard is inefficient, painful, and risky, leaving a significant unmet need in dental implantology.

Kervalion: The future of dental implant surgery with next-generation biobased bone grafts

Kervalion has developed a 3D-printed, bio-based bone graft designed to fit precisely into the patient’s jaw, supporting guided bone regeneration. The graft gradually integrates with the patient’s own bone over 6–12 months, avoiding multiple surgeries and providing a safer, more predictable outcome.

• Patient Benefits: One surgery instead of multiple interventions, faster recovery, less pain, and fewer post-operative visits
• Practitioner Benefits: Simplified procedure that general dentists can perform safely, improved success rates and fewer re-interventions, freeing up time and increasing clinical efficiency
• Healthcare and Distributor Benefits: Lower treatment costs through fewer surgeries and infections, improved patient access, and an innovative product that enhances the portfolio for distribution partners

Kervalion’s supporters and milestones validate our potential for success

We are establishing Kervalion Academy in Europe and the US to provide hands-on training in dental implant procedures, endorsed and guided by leading academic KOLs. To date, 12 practitioners – including Pr. Cuisinier from Montpellier and Dr. Benahmou from Paris – have invested in the company and actively participate in the Academy, demonstrating strong market interest and practitioners’ engagement.

Additionally, Kervalion has filed three patents protecting graft composition, geometry, and fixation methods. Preclinical studies in rat models show promising results in bone regeneration and graft integration.

Seed financing of €500K plus a leveraged €1M is supporting R&D, regulatory preparation, and clinical development. The dental bone graft market is projected to reach $6.68 billion by 2032, with clear potential to expand into orthopaedics, a market three times larger than the dental bone graft market.

Why invest today in Kervalion?

• Clear market needs and adoption potential: Jawbone deficiency affects half of dental implant patients, and current grafting methods are suboptimal, making the Kervalion solution highly relevant and likely to be adopted.
• Scalable mixed business model: Direct sales in Florida where an affiliate will be incorporated early 2027 and from which we will collect direct valuable market information. Florida, in the top 3 incorporation hot spots, has the right and dynamic ecosystem with key dental palyers, and ideal targetted population; Partnerships with major distributors elsewhere to speed up the market take off.
• Growing, addressable market: The dental bone graft market is expanding, and the solution can be scaled into orthopaedics, offering significant incremental growth potential.
• Credible development path: The company has a clear plan for regulatory toxicology studies, first human trials in Brazil, establishment of a US affiliate (Dr. Devillers will be moving to the US for that purpuse early 2027), and US/CE certifications, paving the way for initial commercialisation in 2028.

Early-stage investors can join before large-scale commercialisation, benefiting from strong technical validation, market interest, and a clearly defined path for growth with a still moderate company valuation.

Kervalion offers a practical, scientifically grounded solution to a widespread clinical problem. By simplifying and improving dental implant procedures, the company benefits patients, practitioners, healthcare systems, and distributors, while presenting a compelling investment case in a growing MedTech market.